07:48 AM EDT, 07/08/2024 (MT Newswires) -- Xeris Biopharma ( XERS ) said Monday it has appointed Chief Operating Officer John Shannon to succeed Paul Edick as Chief Executive Officer, effective August 1.

Edick will retire as Chairman and CEO and serve as a senior advisor to Xeris through February 1, 2026.

The Company also appointed Marla Persky as the Chairperson of the Board, effective August 1.

Xeris reported its preliminary second quarter total revenue to exceed $47 million, representing more than 23% growth over last year. It reaffirmed its year-end 2024 cash guidance of $55 million to $75 million.

Price: 2.1700, Change: +0.06, Percent Change: +2.84